Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity

• Published in: Cancer research (Chicago, Ill.) Ill.), 2021-10, Vol.81 (19), p.4901-4909
• Main Authors: Ketola, Kirsi, Kaljunen, Heidi, Taavitsainen, Sinja, Kaarijärvi, Roosa, Järvelä, Emmi, Rodríguez-Martín, Bernardo, Haase, Kerstin, Woodcock, Dan J, Tubio, Jose, Wedge, David C, Nykter, Matti, Bova, G Steven
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Autopsy; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Clonal Evolution - genetics; CpG Islands; Disease Management; Disease Susceptibility; DNA Methylation; Drug Resistance, Neoplasm - genetics; Epigenesis, Genetic; Gene Silencing; Genetic Heterogeneity; Genomics - methods; Humans; Long Interspersed Nucleotide Elements - drug effects; Molecular Targeted Therapy - methods; Neoplasms - diagnosis; Neoplasms - genetics; Neoplasms - mortality; Priority Report; Retroelements; RNA, Small Interfering - genetics; Treatment Outcome
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-21-0371

Treatment-eradicated cancer subclones have been reported in leukemia and have recently been detected in solid tumors. Here we introduce Differential Subclone Eradication and Resistance (DSER) analysis, a method developed to identify molecular targets for improved therapy by direct comparison of genomic features of eradicated and resistant subclones in pre- and posttreatment samples from a patient with BRCA2-deficient metastatic prostate cancer. FANCI and EYA4 were identified as candidate DNA repair-related targets for converting subclones from resistant to eradicable, and RNAi-mediated depletion of FANCI confirmed it as a potential target. The EYA4 alteration was associated with adjacent L1 transposon insertion during cancer evolution upon treatment, raising questions surrounding the role of therapy in L1 activation. Both carboplatin and enzalutamide turned on L1 transposon machinery in LNCaP and VCaP but not in PC3 and 22Rv1 prostate cancer cell lines. L1 activation in LNCaP and VCaP was inhibited by the antiretroviral drug azidothymidine. L1 activation was also detected postcastration in LuCaP 77 and LuCaP 105 xenograft models and postchemotherapy in previously published time-series transcriptomic data from SCC25 head and neck cancer cells. In conclusion, DSER provides an informative intermediate step toward effective precision cancer medicine and should be tested in future studies, especially those including dramatic but temporary metastatic tumor regression. L1 transposon activation may be a modifiable source of cancer genomic heterogeneity, suggesting the potential of leveraging newly discovered triggers and blockers of L1 activity to overcome therapy resistance. SIGNIFICANCE: Differential analysis of eradicated and resistant subclones following cancer treatment identifies that L1 activity associated with resistance is induced by current therapies and blocked by the antiretroviral drug azidothymidine.